Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
AstraZeneca
Johnson and Johnson
Daiichi Sankyo
Express Scripts
Farmers Insurance
Chubb
Mallinckrodt
Moodys

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,927,592

« Back to Dashboard

Which drugs does patent 8,927,592 protect, and when does it expire?

Patent 8,927,592 protects JEVTANA KIT and is included in one NDA.

Protection for JEVTANA KIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-one patent family members in twenty-seven countries.
Summary for Patent: 8,927,592
Title:Antitumoral use of cabazitaxel
Abstract: The invention relates to a compound of formula: ##STR00001## which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.
Inventor(s): Gupta; Sunil (Chester Springs, PA)
Assignee: Aventis Pharma SA (Antony, FR)
Application Number:13/456,720
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,927,592
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,927,592

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,927,592

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 078824 ➤ Try a Free Trial
Australia 2010310986 ➤ Try a Free Trial
Australia 2015200149 ➤ Try a Free Trial
Australia 2016200598 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Cipla
Argus Health
Baxter
Harvard Business School
QuintilesIMS
McKinsey
Covington
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.